Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 170

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 5
Chunk 170
---
 controlled, multinational, multi-center, Phase I/IIa single- and multiple-dose tolerability,
safety and pharmacokinetic study in healthy volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we
will be required to conduct additional clinical trials subject to securing additional financing.

Additionally, the Company entered into research
agreements with scientists from several universities in Israel; two agreements with Yissum and one agreement with BIRAD. For additional
information, see “ Item 4. B. Business Overview - Intellectual Property - License Agreements.”

In addition, the Company has completed a serious
of research programs, with Professor Joseph Tam from the Hebrew University through Yissum for the research of MEAI on food intake, metabolic
and activity profiles. Following the completion of the research program, we and Yissum obtained a jointly owned patent in for which we
entered into a license Agreement in December 2022 in connection with the patent for the use of MEAI in methods for methods for treating
metabolic syndrome titled “use of 5-METHOXY-2-AMINOINDAN (“ MEAI”) in methods for treating metabolic syndrome”.

Also, a research agreement signed with BIRAD, Bar
Ilan University Research and Development Company, in Ramat Gan, Israel, for the research of the safety, efficacy and other characteristics
of MEAI as completed under the leadership of Professor Gal Yadid was also completed. Following the completion of the research program,
we and BIRAD obtained a jointly owned patent in May 2022, for the use of MEAI for the Treatment of Cocaine Addiction titled “ Use
of 5-METHOXY-2-AMINOINDAN (“ MEAI”) in methods for treating cocaine addiction”.

In addition, we have expended our IP portfolio
that now includes nineteen utility patent families including patents and applications having method of use and composition of matter claims.

General and administrative expenses

General and administrative expenses for the year
ended October 31, 2024, amount to $4,362,117, representing a decrease of $397,088, or 8.3%, compared to $4,759,205 for the year ended
October 31, 2023. The decrease resulted primarily from a decrease in investor relations of $1,125,929, a decrease in professional fees
of $212,170, offset by an increase in share-based compensation of $875,324.

Net loss and